scholarly journals An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae

Cell Cycle ◽  
2011 ◽  
Vol 10 (1) ◽  
pp. 118-126 ◽  
Author(s):  
Mustapha Zoubir ◽  
Caroline Flament ◽  
Abdelaziz Gdoura ◽  
Rastilav Bahleda ◽  
Elena Litvinova ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tlr Signaling ◽  
Cyclin Dependent Kinases ◽  
Herpes Viridae

scholarly journals Analysis of the Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Breast Cancer Patients Treated With Cyclin-Dependent Kinases 4 and 6 Inhibitors (CDKi): Limited T-Cell Immunity Despite Satisfactory Humoral Response.

2021 ◽  
Author(s):  
Cristina Saavedra ◽  
Alejandro Vallejo ◽  
Federico Longo ◽  
Juan José Serrano ◽  
María Fernández ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
Humoral Response ◽  
T Cell Immunity ◽  
Breast Cancer Patients ◽  
Cyclin Dependent Kinases ◽  
Cell Immunity ◽  
Chemotherapy Patients ◽  
A Prospective Study

Abstract SARS-CoV-2 vaccination in cancer patients has become crucial because of their higher risk of complications and death from COVID19. We performed a prospective study to assess the immunogenicity of SARS-CoV-2 vaccine in cancer patients treated with CDKi and compared their immune response with patients treated with chemotherapy. While a robust humoral response was observed in the CDKi patients compared with chemotherapy patients, limited T-cell immunity was achieved in both groups.

scholarly journals Efficiency and tolerability of abemaciclib in elderly patients

2020 ◽  
pp. 32-38
Author(s):  
E. I. Kovalenko ◽  
M. V. Khoroshilov ◽  
E. V. Artamonova
Keyword(s):  
Elderly Patients ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Elderly Cancer Patients ◽  
Oncological Treatment ◽  
Cyclin Dependent Kinases ◽  
New Class ◽  
Choice Of Treatment ◽  
Appropriate Therapy ◽  
Geriatric Cancer

Elderly cancer patients represent a very heterogeneous population not only in chronological age, but also in functional status, concomitant diseases and therapy, geriatric syndromes, and, as a consequence, in the tolerability of cancer treatment. The choice of treatment for metastatic breast cancer (mBC) in this category of patients is often a difficult task for oncologists. The emergence of a new class of drugs, inhibitors of cyclin-dependent kinases 4/6 (CDK4/6), has changed the paradigm of treatment of patients with luminal HER2 negative mBC (ER + HER2mBC); however, data on the efficacy and tolerability of these drugs in elderly patients are limited. Pooled subgroup analyzes of studies with CDK4/6 have shown that elderly patients with ER + HER2breast cancer have a clear PFS benefit from the addition of targeted drugs to hormonal therapy. Adverse events are observed more often in combination therapy with increasing age, which requires dose modification and appropriate therapy. In this regard, the drug abemaciclib is very attractive, which is characterized by a lower frequency of neutropenia compared to other CDK4/6 inhibitors, but a higher incidence of diarrhea, which can be controlled by taking appropriate drugs and is not a reason for treatment discontinuation. Careful selection of patients is necessary when deciding on the appointment of any therapy to geriatric cancer patients. Only a comprehensive multidisciplinary approach will make it possible to maximally individualize the approach to the treatment of this difficult category of patients and minimize the likelihood that they will receive excessive or insufficient oncological treatment.

Evaluating the effect of a group pre-treatment chemotherapy psycho-education session for chemotherapy-naive gynecologic cancer patients and their caregivers

2021 ◽  
Vol 160 (1) ◽  
pp. 234-243
Author(s):  
Diana Samoil ◽  
Nazek Abdelmutti ◽  
Lisa Ould Gallagher ◽  
Nazlin Jivraj ◽  
Naa Kwarley Quartey ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Gynecologic Cancer ◽  
Education Session ◽  
Pre Treatment

895: Proteomic Analysis of Sera from Bladder Cancer Patients with MALDI-TOF-MS

2007 ◽  
Vol 177 (4S) ◽  
pp. 297-297
Author(s):  
Kristina Schwamborn ◽  
Rene Krieg ◽  
Ruth Knüchel-Clarke ◽  
Joachim Grosse ◽  
Gerhard Jakse
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Proteomic Analysis ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tof Ms

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document